首页> 美国卫生研究院文献>other >The use of automated Ki67 analysis to predict Oncotype DX risk-of-recurrence categories in early-stage breast cancer
【2h】

The use of automated Ki67 analysis to predict Oncotype DX risk-of-recurrence categories in early-stage breast cancer

机译:使用自动Ki67分析预测早期乳腺癌的Oncotype DX复发风险类别

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Ki67 is a commonly used marker of cancer cell proliferation, and has significant prognostic value in breast cancer. In spite of its clinical importance, assessment of Ki67 remains a challenge, as current manual scoring methods have high inter- and intra-user variability. A major reason for this variability is selection bias, in that different observers will score different regions of the same tumor. Here, we developed an automated Ki67 scoring method that eliminates selection bias, by using whole-slide analysis to identify and score the tumor regions with the highest proliferative rates. The Ki67 indices calculated using this method were highly concordant with manual scoring by a pathologist (Pearson’s r = 0.909) and between users (Pearson’s r = 0.984). We assessed the clinical validity of this method by scoring Ki67 from 328 whole-slide sections of resected early-stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. All patients had Oncotype DX testing performed (Genomic Health) and available Recurrence Scores. High Ki67 indices correlated significantly with several clinico-pathological correlates, including higher tumor grade (1 versus 3, P<0.001), higher mitotic score (1 versus 3, P<0.001), and lower Allred scores for estrogen and progesterone receptors (P = 0.002, 0.008). High Ki67 indices were also significantly correlated with higher Oncotype DX risk-of-recurrence group (low versus high, P<0.001). Ki67 index was the major contributor to a machine learning model which, when trained solely on clinico-pathological data and Ki67 scores, identified Oncotype DX high- and low-risk patients with 97% accuracy, 98% sensitivity and 80% specificity. Automated scoring of Ki67 can thus successfully address issues of consistency, reproducibility and accuracy, in a manner that integrates readily into the workflow of a pathology laboratory. Furthermore, automated Ki67 scores contribute significantly to models that predict risk of recurrence in breast cancer.
机译:Ki67是癌细胞增殖的常用标记,在乳腺癌中具有重要的预后价值。尽管Ki67具有临床重要性,但评估Ki67仍然是一项挑战,因为当前的手动评分方法在用户之间和用户内部差异很大。这种可变性的主要原因是选择偏见,因为不同的观察者将对同一肿瘤的不同区域评分。在这里,我们开发了一种自动的Ki67评分方法,该方法通过使用全玻片分析来识别和评分增殖率最高的肿瘤区域,从而消除了选择偏倚。使用这种方法计算的Ki67指数与病理学家的手动评分(Pearson的r = 0.909)和使用者之间的评分(Pearson的r = 0.984)非常一致。我们通过对328例全切除的早期切除的荷尔蒙受体阳性,人表皮生长因子受体2阴性乳腺癌患者的Ki67评分,评估了该方法的临床有效性。所有患者均进行了Oncotype DX测试(基因组健康)和可用的复发评分。 Ki67指数高与多种临床病理相关性显着相关,包括较高的肿瘤等级(1比3,P <0.001),较高的有丝分裂评分(1与3,P <0.001)以及较低的雌激素和孕激素受体Allred评分(P = 0.002,0.008)。 Ki67指数高也与较高的Oncotype DX复发风险组显着相关(低vs高,P <0.001)。 Ki67指数是机器学习模型的主要贡献者,该模型仅在临床病理学数据和Ki67分数上进行训练时,就以97%的准确性,98%的敏感性和80%的特异性鉴定了Oncotype DX高危和低危患者。因此,Ki67的自动评分可以以易于集成到病理实验室工作流程中的方式成功解决一致性,可重复性和准确性问题。此外,自动Ki67评分对预测乳腺癌复发风险的模型有重要作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号